K. Vandormael

1.1k total citations
13 papers, 833 citations indexed

About

K. Vandormael is a scholar working on Surgery, Economics and Econometrics and Oncology. According to data from OpenAlex, K. Vandormael has authored 13 papers receiving a total of 833 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Surgery, 5 papers in Economics and Econometrics and 4 papers in Oncology. Recurrent topics in K. Vandormael's work include Lipoproteins and Cardiovascular Health (5 papers), Pharmaceutical Economics and Policy (4 papers) and Bone health and treatments (3 papers). K. Vandormael is often cited by papers focused on Lipoproteins and Cardiovascular Health (5 papers), Pharmaceutical Economics and Policy (4 papers) and Bone health and treatments (3 papers). K. Vandormael collaborates with scholars based in United States, Belgium and Germany. K. Vandormael's co-authors include H. A. P. Pols, David A. Hanley, A.M. Galich, Manuel Muñoz‐Torres, Dieter Felsenberg, J Štěpán, Qin-sheng Ge, Terence J. Wilkin, A.J.P. Yates and Rachid Massaad and has published in prestigious journals such as Journal of Allergy and Clinical Immunology, Journal of Bone and Mineral Research and Clinical Pharmacology & Therapeutics.

In The Last Decade

K. Vandormael

13 papers receiving 773 citations

Peers

Countries citing papers authored by K. Vandormael

Since Specialization

Citations

This map shows the geographic impact of K. Vandormael's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Vandormael with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Vandormael more than expected).

Fields of papers citing papers by K. Vandormael

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Vandormael. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Vandormael. The network helps show where K. Vandormael may publish in the future.

Co-authorship network of co-authors of K. Vandormael

This figure shows the co-authorship network connecting the top 25 collaborators of K. Vandormael. A scholar is included among the top collaborators of K. Vandormael based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Vandormael. K. Vandormael is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	PCN193 COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN COMBINATION WITH PLATINUM CHEMOTHERAPY AND PEMETREXED FOR PREVIOUSLY UNTREATED PATIENTS WITH METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN ENGLAND 2019 ·Value in Health ·(unknown), (unknown), (unknown), (unknown), Ashwini Arunachalam, K. Vandormael	2
2	188P Treatment switching–adjusted overall survival (OS) in KEYNOTE-024: First-line pembrolizumab versus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) 2018 ·Journal of Thoracic Oncology ·Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson, Rina Hui, Tibor Csőszi, K. Vandormael, William Malbecq, M. Catherine Pietanza, Julie R. Brahmer	2
3	Predictive Factors for Therapeutic Response to Asthma Treatment with Montelukast or Fluticasone in a Randomized Controlled Trial with Asthmatic Smokers 2012 ·Journal of Allergy and Clinical Immunology ·David Price, Leif Bjermer, Todor A. Popov, Susan Lu, Romana Petrovic, K. Vandormael, Anish Mehta, (unknown), Peter Polos, George Philip	1
4	Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia 2010 ·International Journal of Clinical Practice ·Sukrut Shah, R Češka, Blas Gil Extremera, John F. Paolini, Hilde Giezek, K. Vandormael, (unknown), Christine McCrary Sisk, Darbie Maccubbin	29
5	Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study 2009 ·International Journal of Clinical Practice ·Michel Farnier, Maurizio Averna, Luc Missault, H Vaverková, Margus Viigimaa, Rachid Massaad, K. Vandormael, Amy O. Johnson‐Levonas, Philippe Brudi	51
6	Efficacy of Ezetimibe/Simvastatin 10/40 mg Compared to Doubling the Dose of Low-, Medium- and High-Potency Statin Monotherapy in Patients with a Recent Coronary Event 2008 ·Cardiology ·Philippe Brudi, John Reckless, (unknown), (unknown), Sanghyun Lim, Rachid Massaad, K. Vandormael, Amy O. Johnson‐Levonas	4
7	Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study 2008 ·International Journal of Clinical Practice ·John Reckless, Peter J. Henry, (unknown), Sanghyun Lim, Rachid Massaad, K. Vandormael, Amy O. Johnson‐Levonas, Kinga Lis, Philippe Brudi, Christopher Allen	28
8	Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease 2005 ·International Journal of Clinical Practice ·Vivencio Barrios, Nicolas Amabile, Franck Paganelli, (unknown), Christopher Allen, Amy O. Johnson‐Levonas, Rachid Massaad, K. Vandormael	41
9	Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy 2003 ·SUNScholar (Stellenbosch University) ·(unknown), Núria Guañabens, Seppo Kivinen, (unknown), (unknown), K. Vandormael, (unknown), Mary E. Melton	10
10	Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal‐salt diet 2002 ·Clinical Pharmacology & Therapeutics ·Jules I. Schwartz, K. Vandormael, (unknown), Rubana N. Kalyani, Kenneth C. Lasseter, Gregory B. Holmes, B. J. Gertz, Keith Gottesdiener, Martino Laurenzi, (unknown), Kay Brune	125
11	PATIENT SATISFACTION WITH RIZATRIPTAN VERSUS OTHER TRIPTANS: DIRECT HEAD‐TO‐HEAD COMPARISONS 2001 ·International Journal of Clinical Practice ·(unknown), (unknown), (unknown), K. Vandormael, (unknown), (unknown)	13
12	The Effect of Alendronate on Bone Mass After Distal Forearm Fracture 2000 ·Journal of Bone and Mineral Research ·(unknown), P. Patka, K. Vandormael, H. J. T. M. Haarman, Paul Lips	47
13	Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study 1999 ·Osteoporosis International ·H. A. P. Pols, Dieter Felsenberg, David A. Hanley, J Štěpán, Manuel Muñoz‐Torres, Terence J. Wilkin, Qin-sheng Ge, A.M. Galich, K. Vandormael, A.J.P. Yates, (unknown), (unknown)	480

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact